Evaluation of metabolic syndrome, insulin secretion and insulin resistance in adolescents with overweight and obesity

Yethindra, Vityala; Tagaev, Tugolbai; Zhumabekova, Altynai; Mamatov, Sagynali

doi:10.1016/j.metabol.2021.155011

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is a chronic disease that is increasing in prevalence and is now considered to be a global epidemic. Epidemiologic studies have revealed an association between high body mass index (BMI) and an extensive range of chronic diseases such as Non Alcoholic Fatty Liver (NAFL), cardiovascular disease [1] , [2] , diabetes mellitus [1] , several malignancies [3] , [4] , musculoskeletal diseases [5] , [6] , chronic kidney disease [1] , and mental disorders [7] , [8] , which consequently, affect negatively subjects' quality of life and raise healthcare costs [9] , [10] . Interestingly, it has been demonstrated that BMI 30–40 kg/m 2 is associated with almost 50%, and BMI over 40 kg/m 2 is associated with 100% greater healthcare expenditures due to treatment of obesity comorbidities [11] .…”

Section: Introductionmentioning

confidence: 99%

A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on

2022

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on

2022

View full text Add to dashboard Cite

“…These conditions include diabetes, musculoskeletal issues, chronic renal disease, various types of cancer, mental health disorders, and varicosities, affecting 31-38% of obese individuals. [4,5] It is crucial to create a tailored plan for obese patients during the perioperative phase because to their increased vulnerability to problems compared to persons of normal weight.…”

Section: Original Articlementioning

confidence: 99%

Untitled

2024

AJP

View full text Add to dashboard Cite

Introduction:Overweight adults are 4 times more likely to experience these problems; therefore, restoring normal lung function requires the complete removal of any remaining neuromuscular blockade (NMB) and maintenance of muscle relaxation. This study aimed to identify an effective procedure for NMB in obese patients undergoing abdominal surgery. Materials and Methods: Our study included 34 participants ranging in age from 18 to 56 years, with a mean age of 36.8 ± 2.7 years. The study population comprised of 15 men (45%) and 19 women (55%). Participants were divided into two groups: The control group consisted of 21 individuals with a normal body mass index (BMI), whereas the experimental group consisted of 13 individuals with a BMI that varied between 30.1 and 40.0. Results: Patients in the control group, who responded to T2 and T3 stimulation in the in the four-stimulation mode, received sugammadex (2 mg/kg), totaling 205.90 ± 11.14 mg. The experimental group did not receive any medications to facilitate recovery from NMB. Patients in control group had a quicker recovery time for NMB, averaging 48.00 ± 12.82 minutes, compared to Group 2, which averaged 64.91 ± 4.68 min (t = −4.636; P < 0.0001). Conclusions: After surgery in obese individuals, it is essential to rapidly and absolute revival of NMB and perform neuromuscular monitoring to evaluate the efficacy of removing the muscle relaxant and ensuring that no residual NMB remains.

show abstract

“…Численними дослідженнями переконливо доведено, що зменшення маси тіла більш ніж на 5% вірогідно зменшує рівень артеріального тиску, багатофакторно покращує ліпідний профіль, знижує ризик розвитку ЦД 2-го типу [45]. На противагу цьому, прогресування ожиріння призводить до погіршення якості життя, збільшення частоти інвалідизації і смертності населення [3,48]. Внаслідок цього підвищуються витрати на охорону здоров'я [24,48].…”

unclassified

“…На противагу цьому, прогресування ожиріння призводить до погіршення якості життя, збільшення частоти інвалідизації і смертності населення [3,48]. Внаслідок цього підвищуються витрати на охорону здоров'я [24,48]. Відомо, що ІМТ 30-40 кг/м 2 пов'язаний з майже на 50% більшими щорічними витратами на охорону здоров'я, а ІМТ більше 40 кг/м 2 -на 100% [17].…”

unclassified

The Therapeutic Aspects of Obesity

Bentsa

2023

FMEP

View full text Add to dashboard Cite

The prevalence of obesity has increased worldwide, reaching pandemic levels. More than half of the world’s population will be overweight or obese by 2035 without significant action, according to a report of the World Obesity Federation’s. The World Health Organization defines overweight as body mass index (BMI) >25 kg/m2 and obesity >30 kg/m2 and describes these conditions as abnormal or excessive fat accumulation that is associated with increased health risk. Epidemiologic studies have revealed an association between high BMI and an extensive range of chronic diseases such as non alcoholic fatty liver disease, cardiovascular diseases, diabetes mellitus, several malignancies, musculoskeletal diseases, chronic kidney disease, and mental disorders, which consequently, affect negatively subjects’ quality of life and raise healthcare costs. Obesity as a chronic and progressive lifelong disease requires an active approach to treatment. For obese persons, it is recommended that a diet with an energy deficit of 500 kcal/day and a low energy density should be instituted for the purpose of weight loss and stabilization of a lower weight. More physical exercise in everyday life promotes weight loss and improves risk factors and obesity-associated diseases. Behavior modification and behavioral therapy support changes in nutrition and exercise in everyday life. Pharmacotherapy for obesity can be considered if patients have a BMI of 30 kg/m2 or greater or BMI of 27 kg/m2 or greater with weight-related comorbidities. The choice of the anti-obesity medication needs to take into consideration the patient’s clinical and biochemical profile, co-morbidities, and drug contra-indications, as well as expected degree of weight loss and improvements in cardio-renal and metabolic risk. Successful therapy for obesity depends on tailoring treatment to patients’ behaviors and comorbidities and monitoring of efficacy, safety, and tolerability.

show abstract

Evaluation of metabolic syndrome, insulin secretion and insulin resistance in adolescents with overweight and obesity

Cited by 8 publications

References 0 publications

A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on

A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on

Untitled

The Therapeutic Aspects of Obesity

Contact Info

Product

Resources

About